Purespring is developing gene therapies to halt or prevent kidney disease, one of humankind’s most poorly treated disease areas.
DEVELOPMENT
DEVELOPMENT
Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease.
Purespring’s platform approach enables streamlined gene therapy development for both monogenic and non-monogenic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases.
The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for diseases caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney disease.
Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery.
INVESTORS
OUR INVESTORS
Purespring is funded by leading biotech investors with a strong record of creating and building pioneering companies to transform patients’ lives around the world and has raised £115M to date.
We are well funded to advance our strong pipeline
